Chong Kun Dang's 'Napabeltan' Approved for Phase 2 Clinical Trial in Russia as COVID-19 Treatment

[Asia Economy Reporter Cho Hyun-ui] Chong Kun Dang announced on the 1st that it has received approval from the Russian health authorities to conduct Phase 2 clinical trials to develop the anticoagulant and acute pancreatitis treatment 'Napabeltan' as a treatment for COVID-19.

In this clinical trial, Chong Kun Dang plans to administer Napabeltan for about 10 days to approximately 100 patients with moderate to severe pneumonia caused by COVID-19 to verify its therapeutic effects. A Chong Kun Dang official stated, "We expect to obtain results as early as the end of the year," and added, "If the clinical trial is successful, we plan to apply for emergency approval domestically and overseas for distribution."

The reason Chong Kun Dang selected Russia as the clinical trial country is because more than 5,000 new confirmed cases occur daily in Russia.

The main ingredient of Napabeltan, Nafamostat, was confirmed to have potential as a COVID-19 treatment in drug repositioning research conducted by the Korea Pasteur Institute. The Korea Pasteur Institute announced research results showing that Nafamostat has superior virus infection suppression efficacy compared to Remdesivir, which is used as a COVID-19 treatment.

A Chong Kun Dang official said, "We expect that this clinical trial in Russia will accelerate the development of a COVID-19 treatment," and added, "We will expand clinical trials for COVID-19 treatment development in multiple countries besides Russia by utilizing the global network of the Korea Pasteur Institute."

This content was produced with the assistance of AI translation services.